Your browser doesn't support javascript.
loading
Cooperativity mediated by rationally selected combinations of human monoclonal antibodies targeting the henipavirus receptor binding protein.
Doyle, Michael P; Kose, Nurgun; Borisevich, Viktoriya; Binshtein, Elad; Amaya, Moushimi; Nagel, Marcus; Annand, Edward J; Armstrong, Erica; Bombardi, Robin; Dong, Jinhui; Schey, Kevin L; Broder, Christopher C; Zeitlin, Larry; Kuang, Erin A; Bornholdt, Zachary A; West, Brandyn R; Geisbert, Thomas W; Cross, Robert W; Crowe, James E.
  • Doyle MP; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Kose N; The Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Borisevich V; Department of Microbiology & Immunology, The University of Texas Medical Branch, Galveston, TX 77555, USA; Galveston National Laboratory, The University of Texas Medical Branch, Galveston, TX 77555, USA.
  • Binshtein E; The Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Amaya M; Department of Microbiology & Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
  • Nagel M; Department of Biochemistry, Vanderbilt University, Nashville, TN 37232, USA.
  • Annand EJ; Sydney School of Veterinary Science and Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, Australia; Black Mountain Laboratories & Australian Centre for Disease Preparedness, Health and Biosecurity, CSIRO, Canberra & Geelong, Australia.
  • Armstrong E; The Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Bombardi R; The Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Dong J; The Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Schey KL; Department of Biochemistry, Vanderbilt University, Nashville, TN 37232, USA.
  • Broder CC; Department of Microbiology & Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
  • Zeitlin L; Mapp Biopharmaceutical, Inc., San Diego, CA 92121, USA.
  • Kuang EA; Mapp Biopharmaceutical, Inc., San Diego, CA 92121, USA.
  • Bornholdt ZA; Mapp Biopharmaceutical, Inc., San Diego, CA 92121, USA.
  • West BR; Mapp Biopharmaceutical, Inc., San Diego, CA 92121, USA.
  • Geisbert TW; Department of Microbiology & Immunology, The University of Texas Medical Branch, Galveston, TX 77555, USA; Galveston National Laboratory, The University of Texas Medical Branch, Galveston, TX 77555, USA.
  • Cross RW; Department of Microbiology & Immunology, The University of Texas Medical Branch, Galveston, TX 77555, USA; Galveston National Laboratory, The University of Texas Medical Branch, Galveston, TX 77555, USA.
  • Crowe JE; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; The Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, US
Cell Rep ; 36(9): 109628, 2021 08 31.
Article en En | MEDLINE | ID: mdl-34469726
ABSTRACT
Hendra virus and Nipah virus (NiV), members of the Henipavirus (HNV) genus, are zoonotic paramyxoviruses known to cause severe disease across six mammalian orders, including humans. We isolated a panel of human monoclonal antibodies (mAbs) from the B cells of an individual with prior exposure to equine Hendra virus (HeV) vaccine, targeting distinct antigenic sites. The most potent class of cross-reactive antibodies achieves neutralization by blocking viral attachment to the host cell receptors ephrin-B2 and ephrin-B3, with a second class being enhanced by receptor binding. mAbs from both classes display synergistic activity in vitro. In a stringent hamster model of NiV Bangladesh (NiVB) infection, antibodies from both classes reduce morbidity and mortality and achieve synergistic protection in combination. These candidate mAbs might be suitable for use in a cocktail therapeutic approach to achieve synergistic potency and reduce the risk of virus escape.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antivirales / Receptores Virales / Efrina-B2 / Efrina-B3 / Henipavirus / Infecciones por Henipavirus / Anticuerpos Neutralizantes / Anticuerpos Monoclonales Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antivirales / Receptores Virales / Efrina-B2 / Efrina-B3 / Henipavirus / Infecciones por Henipavirus / Anticuerpos Neutralizantes / Anticuerpos Monoclonales Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Año: 2021 Tipo del documento: Article